AXGT | tickerfilter.com

Fundamental analysis

28%

Profitability 32%

Dept financing 35%

Liquidity 15%

Performance 25%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

0 0%

6 Months

0 0%

1 Year

0 0%

2 Year

0 0%

Key data

Stock price

$2.10

P/E Ratio

N/A

DAY RANGE

$2.10 - $2.10

EPS

-$1.96

52 WEEK RANGE

$1.41 - $6.12

52 WEEK CHANGE

-$57.40

MARKET CAP

84.706 M

YIELD

N/A

SHARES OUTSTANDING

40.336 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

$24,374,843

AVERAGE 10 VOLUME

$2,217,734

AVERAGE 30 VOLUME

$2,692,967

Company detail

CEO: Pavan Cheruvu
Region: US
Website: http://www.axovant.com
Employees: 38
IPO year: -

Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Axovant Gene Therapies Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. Axovant operates through seven wholly owned subsidiaries and also has business operations in Basel, Switzerland and New York, NY. The company was founded on October 31, 2014 and is headquartered in London, United Kingdom.

AXGT - Axovant Gene Therapies Ltd.